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In the current issue of the journal the
p e rsistence of ancient medical pra c-
tices in Mexico is described (1). This
a rt i cle raises an important issue: t h e
large and poorly controlled use of un-
proven or complementary and alterna-
tive medicine (CAM) in the field of
rheumatic diseases. We all know that
among patients suffering from chronic
illnesses, in addition to or instead of
c o nve n t i o n a l , m a i n s t ream medicine,
CAM are often ap p l i e d. The use of
CAM even seems to be growing, des-
pite the trend to use only ev i d e n c e -
based and cost-effe c t ive conve n t i o n a l
medicine (2). Public interest in non-tra-
ditional treatments led the NIH in the
USA to open the Office of Alternative
Medicine (OAM) in 1992, which was
replaced by the National Centre fo r
Complementary and Alternative Medi-
cine (NCCAM) in 1998. The NCCAM
e n c o u rages and fi n a n c i a l ly support s
research on CAM. In the Netherlands,
there is no such national centre.
Although we know that CAM are being
applied frequently, exact numbers on
the extent of usage cannot be given. An
i m p o rtant reason is the pro blem of
defining CAM. On the one hand, CAM
might not only comprise therapies but
also methods of diagnosis and preven-
tion as well as philosophical wo rl d
v i ew s , beliefs and attitudes. On the
other hand, a clear definition of ‘alter-
native’ is not easy to establish either.
The cri t e rion of being ‘ n o n - m a i n-
stream’is not satisfactory: what is non-
mainstream in Europe could be main-
stream in another part of the world, e.g.
acupuncture. The same holds true for
the criterion of not being taught widely
in medical schools or not being gener-
ally available as a treatment modality
in hospitals (3). Nor does the criterion
of not having proven efficacy apply, as
this criterion also applies to some of the
e s t ablished conventional tre at m e n t s .
The definition of the ‘Cochrane Field
in Complementary Medicine’ of CAM
(being ‘diagnosis, treatment and/or pre-
vention wh i ch complements main-
stream medicine by contributing to a
common wh o l e, by satisfying a de-
mand not met by orthodoxy or by di-
versifying the conceptual frameworks
of medicine’) isn’t very helpful in this
respect either. (4). 
In general, CAM is characterised by
methods that haven’t been proven to be
efficient, and are based on theories that
are not congruent with scientific princi-
ples and are not taught in universities.
(5). This generalisation cannot easily
be used for classification, however. Is,
for example a patient applying CAM
when she does not eat pork or drinks no
coffee because she thinks this will ag-
gravate her arthritis? Or someone who
wears a copper bracelet to prevent arth-
ritis? For this reason the only practical
solution is to describe in epidemiologi-
cal or other studies on CAM exactly
wh i ch fo rms of therapies have been
included. The problem then of course
remains that the results of different stu-
dies often cannot be directly compared.
In the Netherlands about 55% of pa-
tients with chronic rheumatic diseases
go to an altern at ive healer and use
CAM at least once during the course of
their disease, while in the general adult
population this percentage is around 20
(6,7). These percentages do not differ
very much from those in other coun-
tries, e.g. the U.S.A., Italy or Mexico
(1,7,8). In addition, the use of alterna-
tive over-the-counter products is wide-
spread (9). The types of CAM applied
of course differ from region to region.
In Mexico more patients will use herbal
re m e d i e s , while in southern Euro p e
more patients seek relief at spa centres
or places of pilgrimage.
How did this situation of the growing
use of and interest in CAM evolve ? In
analysing this, there is the problem that
the factors determining whether a pa-
tient will use CAM or not have not
been fully elucidated. Some hypotheses
exist. First,dissatisfaction with conven-
tional medicine because of ineffective-
ness or adverse effects could play an
i m p o rtant ro l e. Secondly, d i s s at i s fa c-
tion with the attitude of regular medical
doctors. Third, the need for personal
control over the disease (active coping)
could be a determinant to use CAM and
fourth, the philosophical congruence of
theories of CAM with the patients’ val-
ues, world views and beliefs regarding
the disease and therapies (cognitions).
In a Dutch study of RA patients per-
fo rmed some ye a rs ago , r h e u m at o l o-
EDITORIAL Alternative medicine in rheumatology / J.W.G. Jacobs et al.
118
gists received higher scores for attitude
as well as for the effect of treatment
than alternative health care providers
(10). This contradicts the hypothesis of
dissatisfaction as a mean determinant
for the use of CAM. In the USA, like-
wise, a study among patients with vari-
ous diseases showed that the motiva-
tion to use CAM is not dissatisfaction
with conventional medicine (11). In a
random sample of 262 Dutch RA pa-
t i e n t s , those who used CAM we re
younger than those who did not, but
there were no differences regarding the
duration of RA, physical, psychologi-
cal or social functioning or pain cop-
ing. Users of CAM nevertheless per-
ceived a higher impact of RA in several
domains of life, especially psychoso-
cial functioning, c o m p a red to non-
users (12). This finding, that in contrast
to functional capacity the perc e ive d
impact of RA was different in the two
groups, could imply that the perceived
impact of a disease is a determinant to
use CAM. In the USA study as well,
users of CAM reported poorer health
status compared to non-users (11). 
These findings suggest that CAM is not
a substitute for unsatisfactory conven-
tional treatment prescribed by the rheu-
matologist, but that CAM is more con-
gruent than conventional tre at m e n t
with certain pat i e n t s ’ va l u e s , wo rl d
views and beliefs regarding the disease
and therapies. Therefore, one method
to decrease the use of undesired CAM
would seem to be psychosocial inter-
vention and patient education. The lat-
ter especially is needed since increased
use of the Wo rld Wide Web allow s
patients ready access to information of
various levels of scientific reliability on
the subject of CAM as well as more
conventional treatments.
What is and has been the role of clini-
cal trials inve s t i gating the effects of
CAM ? Despite the rising number of
controlled studies, the majority of stud-
ies regarding CAM leave much to be
desired in terms of methodological de-
sign, resulting in false positive claims
(13, 14). Of course, the procedures for
evaluating medicines that are regarded
as products of scientific Western medi-
cine are not always perfect either (5). It
has been argued that the evaluation of
studies on CAM is different and more
difficult compared to studies on regular
m e d i c i n e. Howeve r, in our view the
eva l u ation of the effects of CAM
should in general be quite the same as
for mainstream therapy. Even suppos-
edly beneficial ‘holistic’aspects can be
assessed by quality of life measure-
ments. An important parameter for any
clinical trial is face validity (common
sense). 
A valid explanation of the poor quality
of CAM studies is that relatively few
resources are available for this kind of
research. We do not retain that it is nec-
essary to investigate every single CAM.
However, if there is circumstantial evi-
dence that a certain fre q u e n t ly used
(and expensive) form of CAM may be
beneficial, governments have good rea-
son to promote the investigation of this
CAM (5). Practical collaboration be-
tween CAM practitioners and conven-
tional clinical re s e a rch e rs could im-
prove the quality of such studies. This
collaboration would also reduce defen-
sive attitudes in the face of mutually
perceived hostility and help foster a cri-
tical attitude and research skills in com-
plementary medical practitioners (13). 
The effect of a methodologically sound
clinical trial on the frequency of usage
of the investigated CAM, however, is
limited. If such a study proves that a
certain therapy is effective, it can be-
come recognised as a regular therapy,
as for example in the cases of capsi-
c a i n , hya l u ran and fish oil (15-18).
However, this does not automatically
result in the re i m bu rsement of such
therapies by health insurance compa-
nies. If, on the other hand, in a careful
study a certain CAM does not appear to
have the promised beneficial effect, it
may be removed from the market, as
occurred in the case of enzyme therapy
in the Netherlands after the publication
of our study (19), or it will be disap-
proved of as in the case of zinc and
Greenlip mussels (20, 21). The effect
of studies on the frequency of usage of
CAM that are not reimbursed by health
care systems seems to be limited. The
general lack of belief in the effect of a
remedy does not constitute an obstruc-
tion to its use, as reflected in the popu-
l a rity of copper bracelets among
rheumatic patients in Mexico (1). In-
deed, most patients do not expect heal -
ing of their disease, only the relief of
pain, and this is often achieved through
a placebo response (22). 
One could argue that the lack of proven
efficacy and an unknown mode of ac-
tion (if any) are not reasons per se to
disapprove of the use of a CAM, as
long as there are no high costs, interac-
tions or adverse effects involved and as
long as the CAM does not induce phys-
ical or psychological dependence or the
w i t h d rawal of therapies with prove n
effect. A CAM, even if it does not pro-
duce the effects it is used for, could
improve the quality of life. On the other
hand, certain CAM, especially herbs,
may have serious side effects (1). Ex-
amples are the harmful intera c t i o n s
between St. John’s wort and drugs like
indinavira and cyclosporin (23,24). In
this respect, some CAM do not differ
very much from conventional drugs.
What are the lessons to be learned
from this?
First, dissatisfaction with conventional
medicine doesn’t seem to play a major
role in the decision to use CAM. We
must continue to try to deliver to our
patients the highest quality of therapy
and care against the undertow of in-
creasing financial limitations, but we
cannot expect that this will seriously
reduce the use of CAM.
Secondly, if the main determinants of
CAM are the pat i e n t ’s va l u e s , wo rl d
views and beliefs regarding disease and
therapies, it probably will not be suffi-
cient to refer to scientific principles and
discuss CAM in the light of evidence-
based medicine to dissuade the patient
from using them. We must take into
account the patient's cognitions and
frames of reference in the discussion of
CAM. Open communication between
the patient and doctor will result in bet-
ter insight into the ideas of the patient
and will also improve compliance with
regular therapy (25). A real or per-
ceived negative attitude of the rheuma-
t o l ogist towa rds CAM will simply
cause a patient to stop informing him or
her about their use of such remedies.
This is undesirable because it is impor-
tant to educate patients and warn them
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against possible side effects. 
A pragmatic attitude for the rheumatol-
ogist to take in a discussion with a pa-
tient is to report whether the CAM has
been investigated, whether efficacy has
been shown and what the possible side
effects are. In cases where the method
has not been investigated, the rheuma-
tologist could try to provide a rough
estimate as to whether efficacy may at
least be probable or not, and whether
side effects are probable. Especially in
cases wh e re an effect has not been
proven or has been proven to be absent,
it is in our view wise to advise the pa-
tient to address the following questions
( wh i ch with little modifi c ation also
apply to conventional medicine) before
making a decision:
Wh at are the regular medical tre at-
ments available as an alternative to the
CAM ?
What effects of the CAM can be ex-
pected – on pain, on other symptoms,
and on the course of the disease?
How safe is it ? Which are the possible
side effects and interactions with con-
ventional drugs?
Are there individual patient’s charac-
teristics that could influence the possi-
ble positive or negative effects of the
CAM ?
How long does the CAM have to be
applied before any effect is evident?
How expensive is it and will it be reim-
bursed?
Of course, the normal out-patient visit
is limited in time and a major change in
the patient’s beliefs cannot be estab-
lished in 10 to 15 minutes. Education
should therefore not be limited to out-
p atient visits. Documentation ab o u t
CAM couched in simple terms and in
the native language should be available
to patients (26). Consensus on CAM in
the medical society is a requirement to
avoid contradictory advice from differ-
ent doctors (27). Increased use of the
World Wide Web offers a modern edu-
cational tool for rheumatological soci-
eties: scientifically reliable information
on the subject of CAM can be provided
for patients and rheumatologists on the
internet sites of medical societies, arth-
ritis foundations and health care pro-
viding systems (28). Rheumatologists
will need to have knowledge regarding
the (side) effects of CAM in rheumatic
disorders in order to be able to give
well-founded advice to patients. Know-
ledge of non-conventional medicine in
rheumatic diseases is a criterion of the
European Board of Rheumatology core
c u rriculum cri t e ria. This means that
CAM must become part of the medical
curriculum of the rheumatologist.
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